Results of a Dose‐Finding Phase 1b Study of Subcutaneous Atezolizumab in Patients With Locally Advanced or Metastatic Non–Small Cell Lung Cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Results of a Dose‐Finding Phase 1b Study of Subcutaneous Atezolizumab in Patients With Locally Advanced or Metastatic Non–Small Cell Lung Cancer

Published:2021-03-31 Issue:10 Volume:10 Page:1142-1155
ISSN:2160-763X
Container-title:Clinical Pharmacology in Drug Development
language:en
Short-container-title:Clinical Pharmacology in Drug Development

Author:

Felip Enriqueta¹,Burotto Mauricio²,Zvirbule Zanete³,Herraez‐Baranda Luis A.⁴,Chanu Pascal⁵,Kshirsagar Smita⁶,Maiya Vidya⁶,Chan Phyllis⁶,Pozzi Emanuela⁴,Marchand Mathilde⁷,Monchalin Marion⁴,Tanaka Kunihiko⁶,Tosti Nadia⁴,Wang Bei⁶,Restuccia Eleonora⁴

Affiliation:

1. Vall d'Hebron University Hospital and Institute of Oncology (VHIO) UVic‐UCC, IOB‐Quiron Barcelona Spain

2. Centro de Investigación Clínica Bradford Hill Santiago Chile

3. Riga Eastern Clinical University Hospital Riga Latvia

4. F. Hoffmann‐La Roche, Ltd. Basel Switzerland

5. Genentech/Roche Lyon France

6. Genentech, Inc. South San Francisco California USA

7. Certara Strategic Consulting Paris France

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpdd.936

Reference48 articles.

1. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

2. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

3. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

4. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

5. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Landscape of Subcutaneous Administration Strategies for Monoclonal Antibodies in Oncology;Advanced Materials;2024-08-20

2. An Evidence-Based Rationale for Dose De-escalation of Subcutaneous Atezolizumab;Targeted Oncology;2024-07-31

3. The evolving posology and administration of immune checkpoint inhibitors: subcutaneous formulations;Trends in Cancer;2024-07

4. Brief Report: Updated Data From IMscin001 Part 2, a Randomized Phase III Study of Subcutaneous Versus Intravenous Atezolizumab in Patients With Locally Advanced or Metastatic NSCLC;Journal of Thoracic Oncology;2024-05

5. Subcutaneous delivery of immune checkpoint inhibitors: new route replacing intravenous administration?;Translational Lung Cancer Research;2024-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3